Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
BIBC
1 other identifier
observational
50
1 country
1
Brief Summary
\- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2012
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2012
CompletedFirst Submitted
Initial submission to the registry
July 21, 2012
CompletedFirst Posted
Study publicly available on registry
July 30, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2014
CompletedJuly 30, 2012
July 1, 2012
2 years
July 21, 2012
July 25, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Objective Response Rate
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
From enrollment to disease progression
Secondary Outcomes (1)
overall response
From enrollment to disease progression
Study Arms (1)
bevacizumab combined neoadjuvant chemotherapy
Interventions
The patients will be treated with Avastin combined neoadjuvant chemotherapy
Eligibility Criteria
Breast cancer patients of vascular endocrine surgery department in Xijing Hospital
You may qualify if:
- HER2-negative breast cancer patients
- Without surgery
- Plans to neoadjuvant chemotherapy
You may not qualify if:
- HER2-positive breast cancer patients
- Post-operative patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- LiNanlin,Ph.D, Chief Physician,Clinical Professorlead
- Roche Pharma AGcollaborator
Study Sites (1)
Xijing Hospital ， Fourth Military Medical University
Xi'an, Shaanxi, 710032, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- The department of Vascular endocrine surgery
Study Record Dates
First Submitted
July 21, 2012
First Posted
July 30, 2012
Study Start
June 1, 2012
Primary Completion
June 1, 2014
Study Completion
September 1, 2014
Last Updated
July 30, 2012
Record last verified: 2012-07